$6.15
00.00%
Pre-Market: Jul 19, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Cytek Biosciences
CTKBNASDAQ
Cytek Biosciences (NASDAQ:CTKB) Stock, Analyst Ratings, Price Targets, Forecasts
Cytek Biosciences Inc has a consensus price target of $12.5 based on the ratings of 7 analysts. The high is $28 issued by Piper Sandler on August 17, 2021. The low is $7 issued by Morgan Stanley on November 9, 2023. The 3 most-recent analyst ratings were released by Piper Sandler, Piper Sandler, and Goldman Sachs on May 13, 2024, March 6, 2024, and February 29, 2024, respectively. With an average price target of $9.5 between Piper Sandler, Piper Sandler, and Goldman Sachs, there's an implied 54.47% upside for Cytek Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Goldman Sachs
Stephens & Co.
Morgan Stanley
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Cytek Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2024 | Buy Now | 38.21% | Piper Sandler | David Westenberg | $10 → $8.5 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | 62.6% | Piper Sandler | David Westenberg | $11 → $10 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 62.6% | Goldman Sachs | Matthew Sykes | $9 → $10 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | 46.34% | Stephens & Co. | Mason Carrico | → $9 | Initiates | → Overweight | Get Alert |
| 11/09/2023 | Buy Now | 13.82% | Morgan Stanley | Tejas Savant | $8 → $7 | Maintains | Equal-Weight | Get Alert |
| 10/24/2023 | Buy Now | 30.08% | Morgan Stanley | Tejas Savant | $13 → $8 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | Buy Now | 62.6% | Piper Sandler | David Westenberg | $15 → $10 | Maintains | Overweight | Get Alert |
| 07/19/2023 | Buy Now | — | Raymond James | Andrew Cooper | — | Initiates | → Market Perform | Get Alert |
| 05/11/2023 | Buy Now | 111.38% | Morgan Stanley | Tejas Savant | $14 → $13 | Maintains | Equal-Weight | Get Alert |
| 05/10/2023 | Buy Now | 95.12% | Goldman Sachs | Matthew Sykes | $14 → $12 | Maintains | Buy | Get Alert |
| 03/07/2023 | Buy Now | 143.9% | Piper Sandler | David Westenberg | $18 → $15 | Maintains | Overweight | Get Alert |
| 03/02/2023 | Buy Now | 127.64% | Morgan Stanley | Tejas Savant | $15 → $14 | Maintains | Equal-Weight | Get Alert |
| 03/02/2023 | Buy Now | 127.64% | Goldman Sachs | Matthew Sykes | $16 → $14 | Maintains | Buy | Get Alert |
| 08/18/2022 | Buy Now | 160.16% | Piper Sandler | David Westenberg | $12 → $16 | Maintains | Overweight | Get Alert |
| 08/12/2022 | Buy Now | 143.9% | Morgan Stanley | Tejas Savant | $11 → $15 | Maintains | Equal-Weight | Get Alert |
| 08/11/2022 | Buy Now | 176.42% | Goldman Sachs | Matthew Sykes | $15 → $17 | Maintains | Buy | Get Alert |
| 07/14/2022 | Buy Now | 143.9% | Goldman Sachs | Matthew Sykes | $12 → $15 | Maintains | Buy | Get Alert |
| 05/16/2022 | Buy Now | 95.12% | Piper Sandler | David Westenberg | $17 → $12 | Maintains | Overweight | Get Alert |
| 05/13/2022 | Buy Now | 78.86% | Morgan Stanley | Tejas Savant | $18 → $11 | Maintains | Equal-Weight | Get Alert |
| 05/12/2022 | Buy Now | 95.12% | Goldman Sachs | Matthew Sykes | $14 → $12 | Maintains | Buy | Get Alert |
| 04/13/2022 | Buy Now | 127.64% | Goldman Sachs | Matthew Sykes | $28 → $14 | Maintains | Buy | Get Alert |
| 02/15/2022 | Buy Now | 192.68% | Morgan Stanley | Tejas Savant | $27 → $18 | Maintains | Equal-Weight | Get Alert |
| 08/17/2021 | Buy Now | — | Cowen & Co. | Max Masucci | — | Initiates | → Outperform | Get Alert |
| 08/17/2021 | Buy Now | 322.76% | Morgan Stanley | Tejas Savant | — | Initiates | → Equal-Weight | Get Alert |
| 08/17/2021 | Buy Now | 355.28% | Goldman Sachs | Matthew Sykes | — | Initiates | → Buy | Get Alert |
| 08/17/2021 | Buy Now | 355.28% | Piper Sandler | Steven Marotta | — | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Cytek Biosciences (CTKB) stock?
The latest price target for Cytek Biosciences (NASDAQ:CTKB) was reported by Piper Sandler on May 13, 2024. The analyst firm set a price target for $8.50 expecting CTKB to rise to within 12 months (a possible 38.21% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cytek Biosciences (CTKB)?
The latest analyst rating for Cytek Biosciences (NASDAQ:CTKB) was provided by Piper Sandler, and Cytek Biosciences maintained their overweight rating.
When was the last upgrade for Cytek Biosciences (CTKB)?
There is no last upgrade for Cytek Biosciences
When was the last downgrade for Cytek Biosciences (CTKB)?
There is no last downgrade for Cytek Biosciences.
When is the next analyst rating going to be posted or updated for Cytek Biosciences (CTKB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytek Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytek Biosciences was filed on May 13, 2024 so you should expect the next rating to be made available sometime around May 13, 2025.
Is the Analyst Rating Cytek Biosciences (CTKB) correct?
While ratings are subjective and will change, the latest Cytek Biosciences (CTKB) rating was a maintained with a price target of $10.00 to $8.50. The current price Cytek Biosciences (CTKB) is trading at is $6.15, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.